These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
828 related articles for article (PubMed ID: 9514799)
1. Response to salvage treatment in recurrent ovarian cancer treated initially with paclitaxel and platinum-based combination regimens. Roland PY; Barnes MN; Niwas S; Robertson MW; Alvarez R; Austin JM; Kilgore LC; Partridge EE Gynecol Oncol; 1998 Feb; 68(2):178-82. PubMed ID: 9514799 [TBL] [Abstract][Full Text] [Related]
2. Medical therapy of advanced malignant epithelial tumours of the ovary. Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983 [TBL] [Abstract][Full Text] [Related]
3. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial. Kurbacher CM; Bruckner HW; Cree IA; Kurbacher JA; Wilhelm L; Pöch G; Indefrei D; Mallmann P; Andreotti PE Clin Cancer Res; 1997 Sep; 3(9):1527-33. PubMed ID: 9815839 [TBL] [Abstract][Full Text] [Related]
6. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Hoekstra AV; Hurteau JA; Kirschner CV; Rodriguez GC Gynecol Oncol; 2009 Dec; 115(3):377-81. PubMed ID: 19800107 [TBL] [Abstract][Full Text] [Related]
11. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group. du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222 [TBL] [Abstract][Full Text] [Related]
12. [Experience in first-line chemotherapy with paclitaxel for the treatment of ovarian carcinomas]. Pete I; Szánthó A; Mayer A; Thurzó L; Pulay T Orv Hetil; 2003 May; 144(19):919-24. PubMed ID: 12809068 [TBL] [Abstract][Full Text] [Related]
13. Randomized study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group comparing quality of life in patients with ovarian cancer treated with cisplatin/paclitaxel versus carboplatin/paclitaxel. Greimel ER; Bjelic-Radisic V; Pfisterer J; Hilpert F; Daghofer F; du Bois A; J Clin Oncol; 2006 Feb; 24(4):579-86. PubMed ID: 16446330 [TBL] [Abstract][Full Text] [Related]